It took decades for hepatitis B research to deliver a slate of late-stage candidates capable of reining the disease in.
With Covid-19, the same timeline has devoured all of 5 months. And the outcome will influence the lives of billions of people and a multitrillion-dollar world economy.
Count the economists at Goldman Sachs as optimistic that at least one of these leading vaccines will stay on this furiously accelerated pace and get over the regulatory goal line before the end of this year, with a shot at several more near-term OKs. That in turn should lead to the production of billions of doses of vaccines that can created herd immunity in the US by the middle of next year, with Europe following a few months later.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,300+ biopharma pros reading Endpoints daily — and it's free.
August 03, 2020 at 09:53PM
https://endpts.com/jj-gets-a-fresh-ok-for-esketamine-but-is-it-really-the-game-changer-for-depression-trump-keeps-tweeting-about/
J&J gets a fresh OK for esketamine, but is it really the game-changer for depression Trump keeps tweeting about? - Endpoints News
https://news.google.com/search?q=fresh&hl=en-US&gl=US&ceid=US:en
No comments:
Post a Comment